Doctors deal with a lot of X-ray images. They need to spot new diseases. But they also need to remember old ones. This is tricky. It's like trying to learn a new language while not forgetting your mother tongue. Computers face the same problem. They can learn new things. But they often forget old in
Researchers are looking into why so many young people are developing nearsightedness, also known as myopia. This condition is not just about genes. It's also about what's happening in the world around us. Two different sets of data were used to figure this out. One set is old and focuses on clinical
In a move that has sparked debate, two members of the far-right Alternative for Germany (AfD) party are planning a visit to Russia. This trip comes at a time when the party is facing increased scrutiny over its connections to Moscow and allegations, which they strongly deny, of sharing sensitive mil
Crypto markets are feeling the squeeze, with money moving around but not much coming in. Bitcoin is stuck around $103, 000, and other big coins like ZEC, ICP, and QNT are seeing gains. But overall, the market feels like a game of musical chairs—money is just moving from one place to another, not gro
Back pain is not a one-size-fits-all issue. It's a complex problem that affects people differently. To tackle this, researchers are using advanced technology to study how people move. They want to see if there are distinct patterns in how individuals with back pain move their spines. The goal is to
In a surprising move, a high-ranking Fijian diplomat paid a visit to Taiwan this week. Filipo Tarakinikini, Fiji's permanent representative to the United Nations, met with Taiwan's Vice President Hsiao Bi-khim. This visit is quite unusual because Fiji officially recognizes China, which strongly oppo
Kimberly-Clark, a big name in consumer goods, just made a bold move. They bought Kenvue, the company behind Tylenol. But this deal didn't go over well with Wall Street. Their stock took a huge hit, the worst since the big crash in 1987. Shares dropped by 15%, which is a lot. Why did they do it? The
Metsera is at the center of a heated battle between two pharmaceutical giants, Pfizer and Novo Nordisk. It all started when Novo Nordisk made a surprising offer to buy Metsera for $6. 5 billion, even though Metsera had already agreed to a smaller deal with Pfizer. This has led to a legal fight, with
The United States is preparing to ask the United Nations Security Council to penalize seven ships. These ships are accused of breaking UN rules by shipping North Korean coal and iron ore to China. This trade brings in a lot of money for North Korea each year, between $200 million and $400 million.
Virginia is making a bold move to become a top player in the pharmaceutical world. A new center is being built to train thousands of people every year for jobs in this growing industry. This isn't just any training center. It's a big deal because it brings together community colleges and universitie
